Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

DPx Will Acquire Biologics Producer

by Michael McCoy
September 1, 2014 | A version of this story appeared in Volume 92, Issue 35

The pharmaceutical services firm DPx Holdings has agreed to acquire Gallus BioPharmaceuticals, a contract manufacturer of biologic drugs, for an undisclosed sum. Gallus, owned by the investment firm Ridgemont Equity Partners, has about 370 employees at sites in St. Louis and Princeton, N.J. DPx, which was formed earlier this year through the merger of DSM Fine Chemicals and Patheon, says the purchase will increase employment in its biologics division to 550 and add U.S. locations to biologics facilities it operates in Australia and the Netherlands.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.